Lasofoxifene: Evidence of its therapeutic value in osteoporosis

Luigi Gennari, Daniela Merlotti, Vincenzo De Paola, Ranuccio Nuti

Research output: Contribution to journalArticle


Introduction: Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. It is a common disorder in elderly subjects and represents a major public health problem, affecting up to 40% postmenopausal women and 15% of men. Among the several therapeutical interventions, hormone replacement therapy (HRT) was traditionally seen as the gold standard for preventing osteoporotic fractures in postmenopausal women, as well as for the management of menopausal symptoms. However HRT, especially if administered long-term, may lead to an increased risk of breast and, when unopposed by progestins, endometrial cancers. Alternative therapies include bisphosphonates and raloxifene, a selective estrogen receptor modulator (SERM). While the former have been associated with suboptimal adherence, the latter was considerably less potent than estrogen and its effect in the prevention of nonvertebral fractures remain uncertain. Aims: The purpose of this article is to review the clinical trials of lasofoxifene, a new SERM for the treatment of postmenopausal osteoporosis. The medical literature was reviewed for appropriate articles containing the terms "lasofoxifene" and SERMs". Evidence review: There are three (phase II or phase III) clinical trials that clearly demonstrate efficacy and safety of this new SERM in the suppression of bone loss and the prevention of vertebral and nonvertebral fractures. Moreover, lasofoxifene treatment also reduced breast cancer risk and the occurrence of vaginal atrophy. Place in therapy: With its increased potency and efficacy on the prevention of nonvertebral fractures lasofoxifene may be an alternative and cost-effective therapy for osteoporosis in postmenopausal women.

Original languageEnglish
Pages (from-to)113-129
Number of pages17
JournalCore Evidence
Publication statusPublished - 2009


  • Fracture
  • Lasofoxifene
  • Osteoporosis
  • SERM
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology
  • Reviews and References, Medical

Fingerprint Dive into the research topics of 'Lasofoxifene: Evidence of its therapeutic value in osteoporosis'. Together they form a unique fingerprint.

  • Cite this

    Gennari, L., Merlotti, D., De Paola, V., & Nuti, R. (2009). Lasofoxifene: Evidence of its therapeutic value in osteoporosis. Core Evidence, 4, 113-129.